If approved, tapinarof's main rival will be Amgen and its oral PDE4 inhibitor Otezla (apremilast) – acquired for $13.4 billion in 2019 in side deal to Bristol-Myers Squibb's $74 billion takeover ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback